FDA Approvals and Applications Update

Goodwin
Contact

Goodwin

On October 22, 2021, the FDA approved Genentech’s SUSVIMO (ranibizumab injection) for wet age-related macular degeneration (AMD) based on positive results from an open-label Phase III study. According to the Genentech press release, SUSVIMO, previously called Port Delivery System with ranibizumab, offers an alternative route of administration for anti-VEGF in the form of an ocular implant that continuously delivers ranibizumab intravitreally. The SUSVIMO implant may be inserted in a single outpatient procedure and refilled every six months. The Phase 3 data indicated that patients treated with SUSVIMO experienced vision improvements equivalent to those receiving monthly ranibizumab injections.

Additionally, on October 8, 2021, J&J’s Janssen announced the submission of a supplemental BLA to the FDA, seeking an expanded indication for STELARA (ustekinumab) to treat pediatric patients with juvenile psoriatic arthritis. According to the press release, the filing was supported by the extrapolation of data from adult and pediatric studies on psoriatic arthritis and plaque psoriasis. STELARA is currently approved for children 6 and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderately to severely active Crohn’s disease, and adults with moderately to severely active ulcerative colitis.

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.